This interpretation would be consistent with a protective effect of PPARγ agonists on histological activity, despite the lack of association between the PPARγ2 12Ala SNP and insulin resistance in the present series of patients with NAFLD. The gene discussed is PPARG; the disease is Insulin resistance.